Role of non-coding RNAs in classical hodgkin’s lymphoma treated within the EuroNet-PHL-C2 study

The ability to identify these patients at diagnosis or early during therapy is critical for guiding treatment intensity and improving long‑term outcomes while minimizing unnecessary toxicity. MicroRNAs (miRNAs) have emerged as promising biomarkers in HL due to their stability in blood, ease of detection, and central role in regulating gene expression relevant to tumor biology.

This study aims to determine whether specific microRNA (miRNA) expression patterns can serve as predictive and prognostic biomarkers in pediatric Hodgkin lymphoma. It will identify signatures—defined by upregulated oncogenic and/or downregulated tumor‑suppressive miRNAs—associated with inadequate early PET (ERAqPET) responses after two cycles of OEPA chemotherapy. miRNA profiles at diagnosis and during treatment will be compared between ERAqPET‑positive and ERAqPET‑negative patients, and correlated with treatment outcomes to establish a biomarker profile for early risk stratification.